Liquidia Technologies Inc(LQDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LQDA Liquidia Technologies Inc

Market Closed 03-21 16:00:00 EDT

15.12

-0.32

-2.07%

盘后15.12

+0.000.00%

19:56 EDT

High15.62	Low15.08	Vol1.06M
Open15.18	D1 Closing15.44	Amplitude3.50%
Mkt Cap1.28B	Tradable Cap991.08M	Total Shares84.64M
T/O16.12M	T/O Rate1.61%	Tradable Shares65.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"LQDA","market":"US","secType":"STK","nameCN":"Liquidia Technologies Inc","latestPrice":15.12,"timestamp":1742587200000,"preClose":15.44,"halted":0,"volume":1056986,"hourTrading":{"tag":"盘后","latestPrice":15.12,"preClose":15.12,"latestTime":"19:56 EDT","volume":44343,"amount":670467.16,"timestamp":1742601396696},"delay":0,"floatShares":65547889,"shares":84636621,"eps":-1.617348,"marketStatus":"Market Closed","change":-0.32,"latestTime":"03-21 16:00:00 EDT","open":15.18,"high":15.62,"low":15.08,"amount":16115330.707084,"amplitude":0.034974,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.617348,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1742803200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1532577600000,"exchange":"NASDAQ","adjPreClose":15.44,"preHourTrading":{"tag":"盘前","latestPrice":15.38,"preClose":15.44,"latestTime":"07:20 EDT","volume":7524,"amount":112807.06866,"timestamp":1742556017348},"postHourTrading":{"tag":"盘后","latestPrice":15.12,"preClose":15.12,"latestTime":"19:56 EDT","volume":44343,"amount":670467.16,"timestamp":1742601396696},"volumeRatio":1.1227044320327462,"impliedVol":0.811,"impliedVolPercentile":0.496},"requestUrl":"/m/hq/s/LQDA","defaultTab":"news","newsList":[{"id":"2520045543","title":"Liquidia price target lowered to $22 from $23 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2520045543","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520045543?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:15","pubTimestamp":1742472935,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Liquidia (LQDA) to $22 from $23 and keeps a Buy rating on the shares following a Q4 update that the firm sa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/liquidia-price-target-lowered-to-22-from-23-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/liquidia-price-target-lowered-to-22-from-23-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LQDA"],"gpt_icon":0},{"id":"2520434021","title":"Liquidia Price Target Maintained With a $29.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520434021","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520434021?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:40","pubTimestamp":1742467200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LQDA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 06:40 ET (10:40 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"gpt_icon":0},{"id":"2520317864","title":"Liquidia Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2520317864","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520317864?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:17","pubTimestamp":1742465820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LQDA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 06:17 ET (10:17 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"gpt_icon":0},{"id":"2520613436","title":"Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Liquidia Technologies (LQDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520613436","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520613436?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 17:30","pubTimestamp":1742463053,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT – Research Report) and Liqu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbott-laboratories-abt-and-liquidia-technologies-lqda?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-abbott-laboratories-abt-and-liquidia-technologies-lqda?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1914381329.SGD","SG9999004303.SGD","LU2089984988.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","SG9999002232.USD","IE0009355771.USD","BK4082","LU1691799644.USD","LU1721429741.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU2112291526.USD","LU2237957902.USD","BK4585","BK4007","BK4588","LU0122379950.USD","LU0266013472.USD","LU0170899867.USD","BK4568","LU1989763690.USD","ABT","SGXZ23171101.USD","LU1989763427.SGD","BK4566","LU1057294990.SGD","LU1061106388.HKD","BK4504","LU2468319806.SGD","IE0002141913.USD","BK4533","LU2133065610.SGD","LU0234572021.USD","BK4581","LU1721429402.USD","LU0868494617.USD","SG9999002224.SGD","HCSG","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LQDA","BK4137","LU2237957811.SGD","BK4592"],"gpt_icon":0},{"id":"2520482301","title":"Liquidia Files Secondary Common Stock Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2520482301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520482301?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 16:45","pubTimestamp":1742460342,"startTime":"0","endTime":"0","summary":"Liquidia  filed a shelf registration statement with the US Securities And Exchange Commission Wednesday covering the potential resale of up to 1.1 million common shares of the company by certain stockholders from time to time.The company said it will not receive any proceeds from the sale of the shares as it is not selling the securities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LQDA"],"gpt_icon":0},{"id":"2520540108","title":"Q4 2024 Liquidia Corp Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540108","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540108?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 13:01","pubTimestamp":1742446880,"startTime":"0","endTime":"0","summary":"Roger Jeffs; Chief Executive Officer, Director; Liquidia Corp. Michael Kaseta; Chief Financial Officer, Chief Operating Officer; Liquidia Corp. Thank you, Jason. Good morning, everyone, and thank you for joining us today. We believe that 2025 has the potential to be a transformational year for the company as we further build upon the success of 2024, which resulted in the broadening of the tentatively approved label for YUTREPIA to include both the treatment of patients with pulmonary arterial hypertension or PAH and pulmonary hypertension associated with interstitial lung disease or PH-ILD.There are four strategic imperatives that will drive our success and growth, both in the near and long term. These are seeking to obtain final approval and launching new rep in both PAH and PH-ILD as soon as possible after X-ray of the clinical exclusivity on May 23, or just 65 days from now.Secondly, to continue to advance the clinical profile of YUTREPIA to position it as not only the best-in-c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-liquidia-corp-earnings-050120060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LQDA"],"gpt_icon":0},{"id":"2520116185","title":"Needham Raises Liquidia's Price Target to $25 From $19, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2520116185","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520116185?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 02:29","pubTimestamp":1742408964,"startTime":"0","endTime":"0","summary":"Liquidia (LQDA) has an average rating of Buy and mean price target of $24.90, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LQDA"],"gpt_icon":0},{"id":"1114332801","title":"Stock Track | Liquidia Technologies (LQDA) Plunges 6.24% Pre-Market on Disappointing 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1114332801","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114332801?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 21:26","pubTimestamp":1742390790,"startTime":"0","endTime":"0","summary":"Shares of Liquidia Technologies Inc  tumbled 6.24% in pre-market trading on Wednesday following the release of the company's full-year 2024 financial results. The biopharmaceutical firm, which specializes in developing therapies for rare cardiopulmonary diseases, reported figures that fell short of analysts' expectations.Liquidia posted a net loss of $130.4 million, or $1.66 per share, for the year 2024, significantly higher than the FactSet estimate of a $1.55 loss per share. Additionally, the ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LQDA"],"gpt_icon":0},{"id":"1137063175","title":"Stock Track | Liquidia Technologies (LQDA) Plunges 6.24% Pre-Market on Wider-Than-Expected 2024 Loss and Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1137063175","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137063175?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 21:26","pubTimestamp":1742390790,"startTime":"0","endTime":"0","summary":"Shares of Liquidia Technologies Inc  tumbled 6.24% in pre-market trading on Wednesday following the release of its full-year 2024 financial results, which fell short of analysts' expectations. The biopharmaceutical company, focused on developing innovative therapies for rare cardiopulmonary diseases, reported a wider net loss and lower revenue than anticipated.Despite the disappointing financial results, Liquidia provided updates on its product pipeline. The company is targeting final FDA approv","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Liquidia Technologies (LQDA) Plunges 6.24% Pre-Market on Wider-Than-Expected 2024 Loss and Revenue Miss","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LQDA"],"gpt_icon":0},{"id":"2520890541","title":"Liquidia targets final FDA approval of Yutrepia after May 23","url":"https://stock-news.laohu8.com/highlight/detail?id=2520890541","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520890541?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:40","pubTimestamp":1742380833,"startTime":"0","endTime":"0","summary":"Dr. Roger Jeffs, Liquidia’s (LQDA) CEO, said: “Building on our progress this past year, Liquidia has strengthened its financial position, with up t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/liquidia-targets-final-fda-approval-of-yutrepia-after-may-23?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/liquidia-targets-final-fda-approval-of-yutrepia-after-may-23?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LQDA"],"gpt_icon":0},{"id":"2520039709","title":"Earnings Flash (LQDA) Liquidia Posts 2024 Revenue $14M, vs. FactSet Est of $15.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2520039709","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520039709?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:37","pubTimestamp":1742380650,"startTime":"0","endTime":"0","summary":"Earnings Flash (LQDA) Liquidia Posts 2024 Revenue $14M, vs. FactSet Est of $15.9M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LQDA"],"gpt_icon":0},{"id":"2520903972","title":"Earnings Flash (LQDA) Liquidia Posts Full Year 2024 Net Loss $1.66 a Share, vs. FactSet Est of $1.55 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2520903972","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520903972?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:37","pubTimestamp":1742380643,"startTime":"0","endTime":"0","summary":"Earnings Flash (LQDA) Liquidia Posts Full Year 2024 Net Loss $1.66 a Share, vs. FactSet Est of $1.55 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LQDA"],"gpt_icon":0},{"id":"2520133909","title":"Corrected: Liquidia FY Net Income USD -130.4 Million (Corrects Period)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520133909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520133909?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:30","pubTimestamp":1742380201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nPLXAFE168:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LQDA","BK4007"],"gpt_icon":0},{"id":"2520081709","title":"Liquidia Q4 Net Income USD -130.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520081709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520081709?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:30","pubTimestamp":1742380201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nPLXAFE168:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LQDA"],"gpt_icon":0},{"id":"2520908468","title":"Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520908468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520908468?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:30","pubTimestamp":1742380200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA3GVTVW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LQDA","BK4007"],"gpt_icon":0},{"id":"2520033549","title":"Press Release: Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520033549","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520033549?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 18:30","pubTimestamp":1742380200,"startTime":"0","endTime":"0","summary":"-- Targeting final FDA approval of YUTREPIA after expiration of. -- Advancing pipeline of inhaled treprostinil products in clinical studies. -- Strengthened financial position by up to $100 million via amendment to. Dr. Roger Jeffs, Liquidia's Chief Executive Officer, said: \"Building on our progress this past year, Liquidia has strengthened its financial position, with up to an additional $100 million available pursuant to an amendment to its existing financing agreement with HCRx, while remaining poised for the potential approval and commercialization of YUTREPIA after the expiration on May 23, 2025 of the regulatory exclusivity that is currently preventing final approval. We continue to have our sights set on fulfilling our promise to provide physicians and patients with what we believe can be a much-needed therapeutic alternative, and potentially the prostacyclin of first choice, for patients with PAH and PH-ILD.\". Liquidia continues to progress clinical studies of L606  inhalation ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","R","03160","BK4007","LQDA","BK4099","BK4232","BK4585","BK4555","TM","BK4604","BK4588","BK4202","BK4022"],"gpt_icon":0},{"id":"2520620878","title":"Liquidia Corporation Strengthens Financial Position by Amending Healthcare Royalty Agreement to Incrementally Add up to $100 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520620878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520620878?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 20:06","pubTimestamp":1742299593,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q1086:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LQDA","BK4007"],"gpt_icon":0},{"id":"2520162791","title":"Press Release: Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520162791","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520162791?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 20:00","pubTimestamp":1742299200,"startTime":"0","endTime":"0","summary":"Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million. Under the terms of the Sixth Amendment, Liquidia will receive $25.0 million at closing with the potential to receive two additional tranches of funding: $50.0 million upon the first commercial sale of YUTREPIA following receipt of final FDA approval for the treatment of PAH and PH-ILD, so long as no injunction has been issued prohibiting Liquidia from commercializing YUTREPIA for either or both of PAH and PH-ILD, and $25.0 million upon the mutual agreement of the parties after achieving aggregate net sales of YUTREPIA in excess of $100 million at any time on or prior to June 30, 2026.As consideration for the additional $25.0 million funded at closing, Liquidia has agreed to a fixed payment schedule that terminates in 2032. Payments on the last two tranches, when funded, would also follow a fixed payment schedule. The aggregate payments to HCRx are capped","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4232","BK4555","BK4007","03160","BK4022","BK4604","TM","BK4588","R","BK4099","LQDA"],"gpt_icon":0},{"id":"2520222523","title":"Liquidia Corp  expected to post a loss of 37 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2520222523","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520222523?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 20:37","pubTimestamp":1742215026,"startTime":"0","endTime":"0","summary":"Liquidia Corp  expected to post a loss of37cents a share - Earnings Preview Liquidia Corp LQDA.OQ LQDA.O is expected to show a rise in quarterly revenue when it reports  results on March 19 for the pe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nL8N3Q00XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA"],"gpt_icon":0},{"id":"2520889517","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520889517","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520889517?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 18:00","pubTimestamp":1742205600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Bitcoin Depot Inc.                               4Q       .02   8:05 AM. ·IHS Hldg Ltd.                                    4Q       .01   6:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA","AUTL","SPRY","HYPR","DERM","SGMO","OABI","NRXP","SCPH","LVTX","FLUX","LEN.B","CBUS","LXEO","SIG","KOPN","PL","CAL","SAIC","BCAB","STNE","LPRO","CNTX","STTK","LAR","IMTX","BTM","ANRO","MSIF","CELC","KLC","GLUE","RWAY","FIVE","DRI","AEVA","OSS","RANI","BLTE","DMAC","ASO","PHUN","INO","RBOT","NOA","OPTN","ABSI","CMC"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.liquidia.com","stockEarnings":[{"period":"1week","weight":0.0478},{"period":"1month","weight":-0.0847},{"period":"3month","weight":0.3622},{"period":"6month","weight":0.5196},{"period":"1year","weight":-0.069},{"period":"ytd","weight":0.2857}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0799},{"period":"3month","weight":-0.046},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.08},{"period":"ytd","weight":-0.0377}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.06042},{"month":2,"riseRate":0.857143,"avgChangeRate":0.087227},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.041441},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.075222},{"month":5,"riseRate":0.833333,"avgChangeRate":0.15291},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.059983},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.087113},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.013548},{"month":9,"riseRate":0.428571,"avgChangeRate":0.082402},{"month":10,"riseRate":0.571429,"avgChangeRate":0.019418},{"month":11,"riseRate":0.714286,"avgChangeRate":0.037106},{"month":12,"riseRate":0.714286,"avgChangeRate":0.164224}],"exchange":"NASDAQ","name":"Liquidia Technologies Inc","nameEN":"Liquidia Technologies Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Liquidia Technologies Inc(LQDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Liquidia Technologies Inc(LQDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Liquidia Technologies Inc,LQDA,Liquidia Technologies Inc股票,Liquidia Technologies Inc股票老虎,Liquidia Technologies Inc股票老虎国际,Liquidia Technologies Inc行情,Liquidia Technologies Inc股票行情,Liquidia Technologies Inc股价,Liquidia Technologies Inc股市,Liquidia Technologies Inc股票价格,Liquidia Technologies Inc股票交易,Liquidia Technologies Inc股票购买,Liquidia Technologies Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Liquidia Technologies Inc(LQDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Liquidia Technologies Inc(LQDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction